Drug intelligence / Profile preview

Anocovax

Development stage: Unknown
Lead developer: National Research Centre on Equines
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Anocovax is India's first indigenous COVID-19 vaccine developed specifically for animals. It is an inactivated SARS-CoV-2 Delta (COVID-19) vaccine that contains inactivated SARS-CoV-2 (Delta) antigen with Alhydrogel as an adjuvant. The immunity induced by Anocovax neutralizes both the Delta and Omicron variants of SARS-CoV-2. It has been deemed safe for use in various animal species, including dogs, lions, leopards, mice, and rabbits. The vaccine was developed by the ICAR-National Research Centre on Equines (NRCE) in Haryana, India.

Beyond the preview

Go deeper on Anocovax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anocovax.

Explore the full profile